An orally bioavailable positive allosteric modulator of mGluR4 (EC50 = 1 μM); has a greater than 30-fold selectivity for mGluR4 over mGluR5 in vitro; has no activity at concentrations up to 10 μM at A2A, 5-HT1A, or α2A-adrenergic receptors; reduces catalepsy in a haloperidol-induced catalepsy rat model of Parkinson's disease (ED50 = ~1 mg/kg); leads to downregulation of GRM4 and GABRA1 in rat brain without affecting hippocampal-dependent memory